These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22910968)

  • 21. An optical method for continuous monitoring of the dissolution rate of pharmaceutical powders.
    Laitinen R; Lahtinen J; Silfsten P; Vartiainen E; Jarho P; Ketolainen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):181-9. PubMed ID: 20116958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
    Yang SG
    Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biorelevant in-vitro performance testing of orally administered dosage forms.
    Reppas C; Vertzoni M
    J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results.
    Ruiz ME; Conforti P; Fagiolino P; Volonté MG
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):476-85. PubMed ID: 20878879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
    Seidlitz A; Weitschies W
    J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. USP standards for dissolution and bioavailability.
    Grady LT
    Am J Hosp Pharm; 1982 Sep; 39(9):1546-8. PubMed ID: 7137198
    [No Abstract]   [Full Text] [Related]  

  • 29. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE
    Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles.
    Vaisman M; Spina LD; Eksterman LF; dos Santos MJ; Lima JS; Volpato NM; da Silva RL; de Brito AP; Noël F
    Arzneimittelforschung; 2001; 51(3):246-52. PubMed ID: 11304941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects.
    Wong J; Brugger A; Khare A; Chaubal M; Papadopoulos P; Rabinow B; Kipp J; Ning J
    Adv Drug Deliv Rev; 2008 May; 60(8):939-54. PubMed ID: 18343527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bioavailability of two oral formulations of ranitidine.
    Flores-Murrieta FJ; Toledo A; del Carmen Carrasco-Portugal M; Reyes-García G; Rodríguez-Silverio J; Medina-Santillán R; Herrera JE
    Biopharm Drug Dispos; 2006 Jan; 27(1):23-7. PubMed ID: 16278926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The importance of micronization in the design of dosage forms II. Pharmaceutical technological considerations].
    Antal I
    Acta Pharm Hung; 2006; 76(3):149-54. PubMed ID: 17094663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
    Cabana BE
    Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.
    Tajiri S; Kanamaru T; Kamada M; Konno T; Nakagami H
    Int J Pharm; 2010 Jan; 383(1-2):99-105. PubMed ID: 19747964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.